secwatch.observer — SEC 8-K summary
======================================

Issuer:     CUMBERLAND PHARMACEUTICALS INC (CPIX)
CIK:        0001087294
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0001628280-24-045807
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Cumberland announces study showing Caldolor reduces adverse drug reactions vs ketorolac
--------------------------------------------------------------------------------

- Study analyzed records of >17M patients; compared 31,046 Caldolor vs 124,184 ketorolac adults.
- Caldolor associated with 45% reduction in renal dysfunction (p<0.001) and 78% fewer hematuria events.
- In pediatric patients, Caldolor showed 51-65% lower rate of adverse drug reactions.
- Caldolor also linked to decreased ER visits and shorter hospital stay for both adults and children.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1087294/000162828024045807/0001628280-24-045807-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1087294/000162828024045807/cpix-20241106.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-045807

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer